文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

siRNA Versus miRNA as Therapeutics for Gene Silencing.

作者信息

Lam Jenny K W, Chow Michael Y T, Zhang Yu, Leung Susan W S

机构信息

Department of Pharmacology & Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.

State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong Kong.

出版信息

Mol Ther Nucleic Acids. 2015 Sep 15;4(9):e252. doi: 10.1038/mtna.2015.23.


DOI:10.1038/mtna.2015.23
PMID:26372022
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4877448/
Abstract

Discovered a little over two decades ago, small interfering RNAs (siRNAs) and microRNAs (miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently been investigated as novel classes of therapeutic agents for the treatment of a wide range of disorders including cancers and infections. Clinical trials of siRNA- and miRNA-based drugs have already been initiated. siRNAs and miRNAs share many similarities, both are short duplex RNA molecules that exert gene silencing effects at the post-transcriptional level by targeting messenger RNA (mRNA), yet their mechanisms of action and clinical applications are distinct. The major difference between siRNAs and miRNAs is that the former are highly specific with only one mRNA target, whereas the latter have multiple targets. The therapeutic approaches of siRNAs and miRNAs are therefore very different. Hence, this review provides a comparison between therapeutic siRNAs and miRNAs in terms of their mechanisms of action, physicochemical properties, delivery, and clinical applications. Moreover, the challenges in developing both classes of RNA as therapeutics are also discussed.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/c2f1c833a11f/mtna201523f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/02e517df0152/mtna201523f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/91f86a4a6454/mtna201523f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/c12ba2a59b7f/mtna201523f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/c2f1c833a11f/mtna201523f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/02e517df0152/mtna201523f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/91f86a4a6454/mtna201523f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/c12ba2a59b7f/mtna201523f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1b6e/4877448/c2f1c833a11f/mtna201523f4.jpg

相似文献

[1]
siRNA Versus miRNA as Therapeutics for Gene Silencing.

Mol Ther Nucleic Acids. 2015-9-15

[2]
Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics.

J Exp Clin Cancer Res. 2021-12-4

[3]
Artificial miRNAs as therapeutic tools: Challenges and opportunities.

Wiley Interdiscip Rev RNA. 2021-7

[4]
Identification and characterization of microRNAs and endogenous siRNAs in Schistosoma japonicum.

BMC Genomics. 2010-1-21

[5]
The Complexity of Posttranscriptional Small RNA Regulatory Networks Revealed by In Silico Analysis of Gossypium arboreum L. Leaf, Flower and Boll Small Regulatory RNAs.

PLoS One. 2015-6-12

[6]
RNAi Therapeutic Platforms for Lung Diseases.

Pharmaceuticals (Basel). 2013-2-6

[7]
Turnover of mature miRNAs and siRNAs in plants and algae.

Adv Exp Med Biol. 2010

[8]
Turnover of Mature miRNAs and siRNAs in Plants and Algae.

Adv Exp Med Biol. 2011

[9]
Computational design of artificial RNA molecules for gene regulation.

Methods Mol Biol. 2015

[10]
A viral suppressor of RNA silencing differentially regulates the accumulation of short interfering RNAs and micro-RNAs in tobacco.

Proc Natl Acad Sci U S A. 2002-11-12

引用本文的文献

[1]
The Multifaceted Role of Extracellular Vesicles in Alzheimer's Disease.

J Neurochem. 2025-8

[2]
Beyond Genes: Mechanistic and Epidemiological Insights into Paternal Environmental Influence on Offspring Health.

Curr Environ Health Rep. 2025-8-9

[3]
Tetrahedron DNA Nanostructures as microRNA Inhibitors to Alleviate Acute Pancreatitis.

JACS Au. 2025-6-20

[4]
MicroRNA-Based Delivery Systems for Chronic Neuropathic Pain Treatment in Dorsal Root Ganglion.

Pharmaceutics. 2025-7-18

[5]
Trends and Commonalities of Approved and Late Clinical-Phase RNA Therapeutics.

Pharmaceutics. 2025-7-12

[6]
MicroRNA-1912 regulates cholesterol homeostasis by targeting PCSK9.

Mol Ther Nucleic Acids. 2025-6-9

[7]
Targeted siRNA Delivery Using Cetuximab-Conjugated Starch for Epidermal Growth Factor Receptor-Driven Head and Neck Squamous Cell Carcinoma.

Small Sci. 2025-5-15

[8]
Research Progress of Epigenetic Modifications in Myopia.

Int J Med Sci. 2025-6-23

[9]
Translocating shRNA: a novel approach to RNA interference with Newcastle disease virus as viral vector.

J Gen Virol. 2025-7

[10]
Riding the wave of innovation: nanotechnology in nucleic acid-based cancer therapy.

3 Biotech. 2025-7

本文引用的文献

[1]
Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation.

Curr Pharm Des. 2015

[2]
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.

Nat Med. 2015-4-13

[3]
Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy.

Int J Nanomedicine. 2015-3-31

[4]
Stimuli-responsive liposomes for the delivery of nucleic acid therapeutics.

Nanomedicine. 2015-8

[5]
Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs.

Nat Commun. 2015-3-6

[6]
Atelocollagen-mediated intravenous siRNA delivery specific to tumor tissues orthotopically xenografted in prostates of nude mice and its anticancer effects.

Nucleic Acid Ther. 2015-4

[7]
Preclinical and clinical development of siRNA-based therapeutics.

Adv Drug Deliv Rev. 2015-6-29

[8]
Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance.

J Control Release. 2014-12-4

[9]
Recent developments in nucleic acid delivery with polyethylenimines.

Adv Genet. 2014

[10]
First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

J Clin Oncol. 2014-11-17

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索